Overview
- Grail disclosed on February 19, 2026 that the NHS‑Galleri trial did not observe its primary endpoint for reducing Stage III–IV cancers and said longer follow‑up may be needed.
- The company’s February disclosure preceded a roughly 50.55% one‑day share collapse on February 20, 2026 that plaintiffs say produced large investor losses.
- A securities class action captioned Robbins v. Grail, Inc., No. 26‑cv‑05428 (N.D. Cal.), was filed on behalf of investors who bought GRAL between May 13, 2025 and February 19, 2026.
- The complaint alleges Grail and certain executives misled markets by overstating confidence in NHS‑Galleri and repeatedly refusing to release detailed topline data that plaintiffs say would have shown trendlines undermining the three‑year readout assumption.
- Multiple law firms are soliciting clients and seeking lead‑plaintiff status ahead of the August 4, 2026 deadline, and the next steps to watch are the court’s appointment of a lead plaintiff and any consolidation of competing complaints.